A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
A Phase Ib, Multicenter, Randomized, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
-
Contact:
- Zhou
- Phone Number: 13939068863
- Email: papertigerhu@163.com
-
-
Hubei
-
Wuhan, Hubei, China
- Recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Zhang
- Phone Number: 15871818568
- Email: Zhangmin35@aliyun.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Recruiting
- The First Affiliated Hospital of Nanchang University
-
Contact:
- Wang
- Phone Number: 13798127917
- Email: wangjieyu19@aliyun.com
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recruiting
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
Contact:
- Xiao
- Phone Number: 022-23909184
- Email: zjxiao@ihcames.ac.cn
-
Tianjin, Tianjin, China
- Recruiting
- The Second Hospital of Tianjin Medical University
-
Contact:
- Bai
- Phone Number: 13820525296
- Email: janebai86@126.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Huang
- Phone Number: 13588010568
- Email: househuang@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients aged 18 years or older at the time of screening.
- A confirmed diagnosis of PV according to the revised 2016 World Health Organization criteria and are resistant to or intolerant of hydroxyurea or Interferon alpha.
- Have a treatment history for PV with resistance or intolerance to hydroxyurea or Interferon alpha.
- Subjects receiving hydroxyurea, Interferon alpha, or ruxolitinib must complete a washout period before administration of the investigational drug.
- Must agree to adhere to appropriate contraception requirements during the study period.
- All female subjects with fertility capacity tested negative for blood pregnancy.
- Voluntarily participate in clinical trials and agrees to participate in the study by giving written informed consent.
Exclusion Criteria:
- The spleen is palpable at least 5 centimeters below the left costal margin upon palpation at baseline.
- Heart failure, unstable angina pectoris, myocardial infarction, and other thrombotic diseases within the 6 months prior to screening.
- Abnormal QTc interval of electrocardiogram within the 6 months prior to screening.
- Uncontrolled hypertension prior to screening.
- Any non-PV myeloproliferative neoplasms (MPN).
- Blast cells and blast granulocytes in the peripheral blood within the 3 months prior to screening.
- Hematological indicators do not meet the requirements at the time of screening.
- Known positive for active hepatitis B, hepatitis C, syphilis or human immunodeficiency virus (HIV) infection.
- History of invasive malignancies within the last 5 years.
- Severe infection or uncontrolled active infection.
- Other hematological and lymphatic system diseases or any diseases causing hemolysis or erythrocyte instability.
- Other systemic diseases or a family history of systemic diseases, may affect the subject's safety or any other diseases and physiological conditions that may affect the results of the study, judged by the investigator.
- Specific history of allergies.
- Subjects who have used monoclonal antibodies within the 6 months prior to screening.
- Patients who have received vaccinations within 6 weeks prior to screening.
- Subjects who have received other antitumor therapeutic drugs for PV prior to screening.
- Chronic diseases requiring treatment with systemic glucocorticoids or other immunosuppressants.
- History of drug abuse or illicit drug use within 3 months prior to screening.
- Participation in other clinical trials within 3 months prior to screening.
- Planned elective surgery during the study.
- History of surgery within 3 months prior to screening.
- Intolerable iron deficiency-related symptoms judged by the investigator prior to the first dosing.
- Pregnant or lactating females; women of reproductive age who are not using effective contraception.
- Individuals directly associated with the research and/or their immediate family members.
- Other factors which may potentially affect the assessment of the study results by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental: Open-label 9MW3011 Dose1
Drug: 9MW3011 9MW3011 for multiple dose via intravenous infusion
|
Multiple dose
|
|
Experimental: Experimental: Open-label 9MW3011 Dose2
Drug: 9MW3011 9MW3011 for multiple dose via intravenous infusion
|
Multiple dose
|
|
Experimental: Experimental: Open-label 9MW3011 Dose3
Drug: 9MW3011 9MW3011 for multiple dose via intravenous infusion
|
Multiple dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Event
Time Frame: Up to 141 or 197 days
|
Incidence of adverse events
|
Up to 141 or 197 days
|
|
Vital sign
Time Frame: Up to 141 or 197 days
|
Incidence of treatment-emergent clinically abnormal vital signs
|
Up to 141 or 197 days
|
|
Physical examination
Time Frame: Up to 141 or 197 days
|
Incidence of treatment-emergent clinically abnormal physical examinations
|
Up to 141 or 197 days
|
|
12-lead electrocardiogram (ECG)
Time Frame: Up to 141 or 197 days
|
Incidence of treatment-emergent clinically significant 12-lead electrocardiograms (ECGs)
|
Up to 141 or 197 days
|
|
Laboratory test result
Time Frame: Up to 141 or 197 days
|
Incidence of treatment-emergent clinically significant laboratory test results
|
Up to 141 or 197 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: Day 1 to Day 141 or 197
|
Plasma maximum measured drug concentration
|
Day 1 to Day 141 or 197
|
|
Tmax
Time Frame: Day 1 to Day 141 or 197
|
Time of maximum concentration
|
Day 1 to Day 141 or 197
|
|
AUC0-τ
Time Frame: Day 1 to Day 141 or 197
|
Area under the plasma concentration-time curve during a dosage interval(τ)
|
Day 1 to Day 141 or 197
|
|
AUC0-t
Time Frame: Day 1 to Day 141 or 197
|
Area under the concentration-time curve from dosing to the last measurable time point
|
Day 1 to Day 141 or 197
|
|
AUC0-∞
Time Frame: Day 1 to Day 141 or 197
|
Area under the concentration-time curve from dosing to infinity
|
Day 1 to Day 141 or 197
|
|
λz
Time Frame: Day 1 to Day 141 or 197
|
Terminal elimination rate constant
|
Day 1 to Day 141 or 197
|
|
t1/2z
Time Frame: Day 1 to Day 141 or 197
|
The terminal elimination half-life
|
Day 1 to Day 141 or 197
|
|
MRT
Time Frame: Day 1 to Day 141 or 197
|
Mean residence time
|
Day 1 to Day 141 or 197
|
|
Vss
Time Frame: Day 1 to Day 141 or 197
|
Volume of Distribution at Steady State
|
Day 1 to Day 141 or 197
|
|
CLss
Time Frame: Day 1 to Day 141 or 197
|
Steady-state clearance
|
Day 1 to Day 141 or 197
|
|
DF
Time Frame: Day 1 to Day 141 or 197
|
Fluctuation percentage
|
Day 1 to Day 141 or 197
|
|
Ctrough
Time Frame: Day 1 to Day 141 or 197
|
Trough Concentration
|
Day 1 to Day 141 or 197
|
|
Rac(AUC)
Time Frame: Day 1 to Day 141 or 197
|
Accumulation ratio calculated from the AUCτ,ss and AUCτ after single dosing
|
Day 1 to Day 141 or 197
|
|
Rac(cmax)
Time Frame: Day 1 to Day 141 or 197
|
Accumulation ratio calculated from the Cmax,ss and Cmax after single dosing
|
Day 1 to Day 141 or 197
|
|
Hepcidin
Time Frame: Day 1 to Day 141 or 197
|
Change from baseline in hepcidin levels
|
Day 1 to Day 141 or 197
|
|
Serum iron
Time Frame: Day 1 to Day 141 or 197
|
Change from baseline in serum iron levels
|
Day 1 to Day 141 or 197
|
|
Transferrin saturation (TSAT)
Time Frame: Day 1 to Day 141 or 197
|
Change from baseline in transferrin saturation (TSAT) levels
|
Day 1 to Day 141 or 197
|
|
Anti-drug antibodies(ADA)
Time Frame: Day 1 to Day 141 or 197
|
The incidence of ADA
|
Day 1 to Day 141 or 197
|
|
Hematocrit (HCT)
Time Frame: Day1 to Day 141 or 197
|
Change from baseline in HCT levels
|
Day1 to Day 141 or 197
|
|
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score(MPN-SAF TSS)
Time Frame: Day 1 to Day 141 or 197
|
Change from baseline in MPN-SAF TSS score
|
Day 1 to Day 141 or 197
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 9MW3011-C03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.